RAGE

RAGE Informations sur la molécule

Nom anglais	Advanced glycosylation end product-specific receptor	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	3	Alias de la cible	Receptor for advanced glycosylation end products，AGER，Advanced Glycosylation End-Product Specific Receptor，RAGE，Receptor For Advanced Glycation End-Products Variant 20，Receptor For Advanced Glycation End-Products，RAGE Isoform NtRAGE-Delta，RAGE Isoform SRAGE-Delta，SCARJ1，Receptor for Advanced Glycation End Products，Advanced glycosylation end product-specific receptor
Phase de R&D la plus avancée	Phase 3 Clinical

Nom anglais	Advanced glycosylation end product-specific receptor
Alias de la cible	Receptor for advanced glycosylation end products，AGER，Advanced Glycosylation End-Product Specific Receptor，RAGE，Receptor For Advanced Glycation End-Products Variant 20，Receptor For Advanced Glycation End-Products，RAGE Isoform NtRAGE-Delta，RAGE Isoform SRAGE-Delta，SCARJ1，Receptor for Advanced Glycation End Products，Advanced glycosylation end product-specific receptor
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	3
Phase de R&D la plus avancée	Phase 3 Clinical

RAGE Liste de produits

Attribut
Cell (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
- (1)
Marqueur
- (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
CHEK-ATP156	Human	HEK293	HEK293/Human RAGE Stable Cell Line				Ajouter au panier

Quantité totale1

RAGEContexte de la molécule

Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.

RAGEAlias de la molécule

AGER,RAGE

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Azeliragon	TTP-488; PF-4494700; PF-04494700	Phase 3 Clinical	Vtv Therapeutics	Alzheimer Disease; Brain metastases; Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Diabetic Nephropathies; Glioblastoma; Glioma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms	Details
TRC-4186	TX-41XX; TRC-4186	Phase 2 Clinical	Torrent Pharmaceuticals Ltd	Diabetes Complications; Heart Failure	Details
ARO-RAGE		Phase 2 Clinical	Arrowhead Pharmaceuticals Inc	Asthma	Details